ArcStone Securities and Investments Corp.’s Post

🌡️ 𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐭𝐡𝐚𝐭 𝐰𝐞 𝐚𝐭 PS Pharma Service GmbH 𝐚𝐥𝐬𝐨 𝐡𝐚𝐯𝐞 𝐚 𝐜𝐨𝐥𝐝 𝐫𝐨𝐨𝐦 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐬𝐚𝐟𝐞 𝐬𝐭𝐨𝐫𝐚𝐠𝐞 𝐨𝐟 𝐧𝐨𝐧-𝐧𝐚𝐫𝐜𝐨𝐭𝐢𝐜𝐬? ❄ 𝐃𝐫𝐮𝐠 𝐬𝐚𝐟𝐞𝐭𝐲: Our cold room maintains a constant temperature of 2 to 8 degrees Celsius to preserve the effectiveness of medicines. ❄ 𝐏𝐫𝐞𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐨𝐧𝐭𝐚𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧: External influences don't stand a chance - your medicines are safe. ❄ 𝐑𝐞𝐩𝐚𝐜𝐤𝐚𝐠𝐢𝐧𝐠: We regularly carry out GMP-compliant repackaging in our cold room. ❄ 𝐂𝐚𝐩𝐚𝐜𝐢𝐭𝐢𝐞𝐬: Our spacious cold room offers space for larger quantities of medicines.   Do you have any questions or would you like to find out more? 𝐈 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐡𝐚𝐩𝐩𝐲 𝐭𝐨 𝐚𝐧𝐬𝐰𝐞𝐫 𝐚𝐧𝐲 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐲𝐨𝐮 𝐦𝐚𝐲 𝐡𝐚𝐯𝐞. #Coldroom #Pharma #Warehousing #GMP #Ozempic #Wegovy

How Independent Pharmacies (Like Yours) Can Boost GLP Prescriptions. Dotti members are achieving remarkable success with our semaglutide marketing materials! And guess what? Soon, we'll also unveil our tirzepatide marketing toolkit. Don't let this game-changing opportunity pass by. Sign up for Dotti today and start transforming your outreach! #pharmdlife #Dotti #Atrium24 #crm #pharmacyowner #semaglutide #tirzepatide

I am quoted in the attached interesting article about counterfeited and compounded versions of Ozempic, Wegovy, Mounjaro, and Zepbound medications.

Stellar article by Liz Vanderveen on the medispa/weight loss trends happening across the US. Three big takeaways for me: 1. If there is an FDA exclusion on the policy, then most compound versions of Semaglutide is going to be excluded. 2. The salt variations can lead to even more internal damage than we currently understand. 3. You need to be upfront with your carriers. Too often I find Medispa's that wait until renewal to loop their carrier in on their new services. It's risky business...

A new study in 𝙅𝘼𝙈𝘼 𝙉𝙚𝙩𝙬𝙤𝙧𝙠 𝙊𝙥𝙚𝙣 reveals alarming risks of buying GLP-1 medications online without a prescription. The findings are startling: Nearly 𝟱𝟬% of websites selling semaglutide are illegal pharmacies. These vendors often operate 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝘃𝗮𝗹𝗶𝗱 𝗹𝗶𝗰𝗲𝗻𝘀𝗲𝘀, selling unregistered or falsified products. Out of six semaglutide products purchased, only three were delivered, with the rest being scams demanding extra payments of $𝟲𝟱𝟬-$𝟭𝟮𝟬𝟬. Quality tests revealed significantly 𝗹𝗼𝘄𝗲𝗿 𝗽𝘂𝗿𝗶𝘁𝘆 𝗹𝗲𝘃𝗲𝗹𝘀 (7%-14%) compared to the advertised 99%. One sample contained 𝗵𝗶𝗴𝗵 𝗹𝗲𝘃𝗲𝗹𝘀 𝗼𝗳 𝗲𝗻𝗱𝗼𝘁𝗼𝘅𝗶𝗻𝘀, indicating serious contamination. Some products had up to 39% more semaglutide per injection than labeled, posing 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗿𝗶𝘀𝗸𝘀. US poison centers report a 𝟭𝟱𝟬𝟬% 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 in semaglutide overdose calls. Key Takeaway: Regulatory enforcement and consumer vigilance are crucial. Purchasing semaglutide online without a prescription can seriously jeopardize your health. FDA and Federal Trade Commission need to greatly increase enforcement in this area. Link to full study below.

From JAMA Network Open, a recent study found 42% of search engine listings for semaglutide sold without a prescription were for illegal pharmacy operations; test purchases resulted in delivery scams flagged by customs, evidence of contamination, dilution, and dosing inaccuracies. #wegovy #ozempic #semaglutide #glp-1 #onlinepharmacy #patientsafety #counterfeits #fakes #authentication https://lnkd.in/en2qgDPc

Aurobindo Pharma USA Recalls Healthy Living Migraine Relief Due to Mislabeling Aurobindo Pharma USA, Inc. has initiated a voluntary nationwide recall of a specific lot of its Healthy Living Migraine Relief product. The recall is due to a critical labeling error, resulting in missing manufacturer information. Product Details: • Healthy Living Migraine Relief: Acetaminophen 250mg, Aspirin 250mg, Caffeine 65mg tablets • Lot number: AC2523005A • Expiration date: June 2025 • Date of recall: 24 july 2024 Risk: The absence of essential product information poses significant risks to consumers, including: • Incorrect dosage administration • Potential drug interactions • Increased risk of adverse reactions Consumer Action: Individuals in possession of the recalled product should immediately discontinue use and contact Aurobindo Pharma USA, Inc. for return instructions. Consumers experiencing adverse reactions should contact their healthcare provider and report the incident to the FDA's MedWatch Adverse Event Reporting program. Company Contact: Aurobindo Pharma USA, Inc. • Phone: 1-866-850-2876 (Option 2) • Email: pvg@aurobindousa.com FDA Announcement: For more details on this recall, please refer to the official FDA announcement: https://lnkd.in/gbFAQTdM #drugrecall #productrecall #healthalert #consumersafety #fdarecall #aurobindopharma #healthylivingmigrainerelief #mislabeling #medicationerror #drugsafety #news #urgent #share #aware #safetyfirst

US medical supply chain in crisis: shortages exist for 300 medicines right now. Pharmacies, hospitals, and patients are scrambling to find must-have doses of drugs. Learn about this growing problem, with a specific focus on the challenges facing the last US factory that is producing a crucial antibiotic, amoxicillin. https://lnkd.in/eGtwBWQ4 #medicalsupplychain #supplychainnews #supplychains #pharma

𝙄𝙣 𝙏𝙝𝙚 𝙉𝙚𝙬𝙨 As reported by NBC News, 𝗮 𝗻𝗲𝘄 𝘀𝘁𝘂𝗱𝘆 𝗿𝗲𝘃𝗲𝗮𝗹𝘀 𝘁𝗵𝗮𝘁 𝟰𝟮% 𝗼𝗳 𝗼𝗻𝗹𝗶𝗻𝗲 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗶𝗲𝘀 𝘀𝗲𝗹𝗹𝗶𝗻𝗴 𝘀𝗲𝗺𝗮𝗴𝗹𝘂𝘁𝗶𝗱𝗲, 𝘁𝗵𝗲 𝗮𝗰𝘁𝗶𝘃𝗲 𝗶𝗻𝗴𝗿𝗲𝗱𝗶𝗲𝗻𝘁 𝗶𝗻 𝘁𝗵𝗲 𝘄𝗲𝗶𝗴𝗵𝘁 𝗹𝗼𝘀𝘀 𝗱𝗿𝘂𝗴 𝗪𝗲𝗴𝗼𝘃𝘆, 𝗮𝗿𝗲 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗶𝗹𝗹𝗲𝗴𝗮𝗹𝗹𝘆. These unlicensed vendors pose significant risks by offering unregulated and potentially unsafe products. Experts warn consumers against buying weight loss drugs online without a prescription due to the high likelihood of encountering scams or receiving dangerous medications. The study highlights the growing black market for semaglutide driven by shortages and high demand. #Health #Pharmacy #WeightLoss #Semaglutide #Wegovy #ConsumerSafety #Healthcare #OnlinePharmacies #FDA #MedicationRisks #Telehealth

FIRST CLASS-ACTION LAWSUIT AGAINST WALGREENS FILED IN SOUTH CAROLINA: On September 4th, two South Carolina residents filed a proposed class-action lawsuit against Walgreens, alleging the retailer failed to warn customers about a carcinogenic ingredient in a common cold medicine. Guaifenesin, the generic for Mucinex, contains the known carcinogen benzene, but Walgreens packaging does not disclose this, according to court documents obtained by Becker's. The plaintiffs said they would not have purchased or would have paid less for the guaifenesin if they had known about the cancer-causing agent. The Walgreens customers seek compensatory, statutory and punitive damages. In the manufacturing of extended-release guaifenesin, thickening agents might contain benzene, according to Bloomberg. For "years", the FDA has warned drugmakers about the risk of benzene contamination, but at least a dozen medications are made with thickening agents — carbomers — that might contain benzene. By 2026, the United States Pharmacopeia plans to omit carbomers that are manufactured with benzene, Bloomberg reported.  #Walgreens #litigation #classAction #Benzene #carcinogen #lawsuit #southcarolina #FDA #knowncarcinogen #thickeningagents #harmful #hazardtohealth #coughsyrup #medicine #cancer #Florida #Medicaid #AHCA